Ruvan-Z is a combination of Rosuvastatin (an HMG-CoA reductase inhibitor or statin) and Ezetimibe (a cholesterol absorption inhibitor). It is indicated in adults as an adjunct to diet for reducing LDL-cholesterol (bad cholesterol) in patients with primary non-familial hyperlipidaemia and for reducing LDL-cholesterol in patients with homozygous familial hypercholesterolaemia, either alone or in combination with other lipid-lowering therapies.

Rosuvastatin works by reducing cholesterol production in the liver and increasing the number of LDL receptors, which enhances the removal of LDL from the bloodstream. Ezetimibe lowers blood cholesterol by inhibiting cholesterol absorption in the small intestine. Together, they provide an effective dual mechanism for cholesterol reduction.

The recommended dosage ranges from 5 mg/10 mg to 40 mg/10 mg once daily, depending on the patient's LDL-C level, treatment goals, and cardiovascular risk profile. Patients with severe renal impairment not undergoing haemodialysis should begin with 5 mg/10 mg once daily and should not exceed 10 mg/10 mg daily. Tablets should be swallowed whole and must not be crushed, chewed, or dissolved.

Concomitant use with Cyclosporine or Gemfibrozil is not recommended. Dose adjustments may be required when used with certain antiviral medicines, Darolutamide, or Regorafenib. Niacin, fibrates, and colchicine may increase the risk of muscle-related adverse effects.

The medicine is contraindicated in patients with active liver disease, decompensated cirrhosis, or hypersensitivity to any component of the formulation.

Common side effects include headache, nausea, muscle pain, joint pain, dizziness, weakness, constipation, abdominal pain, diarrhoea, sinusitis, respiratory tract infections, fatigue, influenza-like symptoms, pain in extremities, and back pain.

Ruvan-Z is contraindicated during pregnancy and is not recommended during breastfeeding.

Important precautions include the risk of myopathy and rhabdomyolysis, especially in elderly patients, those with uncontrolled hypothyroidism, renal impairment, or those receiving higher doses and interacting medicines. Liver enzyme monitoring may be considered before and during treatment when clinically indicated. Patients with severe liver impairment or acute liver failure should not use this medication.